Tanrikulu Azra Meryem, Ozdilek Betul, Agirbasli Mehmet
Clinic of Cardiology, Ministry of Health Maltepe State Hospital, Istanbul, Turkey.
Department of Neurology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Med Princ Pract. 2024;33(6):562-568. doi: 10.1159/000540854. Epub 2024 Aug 12.
The aim of the study was to investigate serum plasminogen activator inhibitor-1 (PAI-1) levels of patients with Parkinson's disease (PD) and their relationship with clinical findings and treatment of disease.
The study included 125 PD patients and 48 healthy controls. Patients have been taking effective dopaminergic treatment regularly. The clinical severity of parkinsonism was assessed using the Hoehn and Yahr (HY) staging scale and the Unified PD Rating Scale (UPDRS). PAI-1 level analysis was performed by enzyme-linked immunosorbent assay.
Patients with PD had significantly lower serum PAI-1 levels than healthy controls (p < 0.001). Correlations with clinical findings showed only a marginally positive correlation between serum PAI-1 and HY score (r = 0.170, p = 0.05). In contrast, no significant correlation was demonstrated with the UPDRS score or other clinical parameters.
This is the first comprehensive analysis of serum PAI-1 levels in patients with PD. The distribution of PAI-1 in PD appears to be complex. The study results implicate that the paradoxical effects of tissue plasminogen activator on the brain parenchyma can be important in the pathophysiology of PD. Future studies are needed to elucidate the role of fibrinolytic system components in PD.
本研究旨在调查帕金森病（PD）患者的血清纤溶酶原激活物抑制剂-1（PAI-1）水平及其与疾病临床表现和治疗的关系。
该研究纳入了125例PD患者和48例健康对照者。患者一直在规律地接受有效的多巴胺能治疗。使用Hoehn和Yahr（HY）分期量表以及统一PD评定量表（UPDRS）评估帕金森病的临床严重程度。通过酶联免疫吸附测定法进行PAI-1水平分析。
PD患者的血清PAI-1水平显著低于健康对照者（p < 0.001）。与临床表现的相关性显示血清PAI-1与HY评分之间仅存在微弱的正相关（r = 0.170，p = 0.05）。相比之下，与UPDRS评分或其他临床参数未显示出显著相关性。
这是对PD患者血清PAI-1水平的首次全面分析。PAI-1在PD中的分布似乎很复杂。研究结果表明组织纤溶酶原激活物对脑实质的矛盾作用在PD的病理生理学中可能很重要。需要进一步研究以阐明纤溶系统成分在PD中的作用。
